Immuntherapie des metastasierten nierenzellkarzinoms. Aktueller stand und indikationen zum klinischen einsatz

R. Heuer; C. Eichelberg; M. Zacharias; H. Heinzer

doi:10.1007/s00761-008-1486-y

Immuntherapie des metastasierten nierenzellkarzinoms. Aktueller stand und indikationen zum klinischen einsatz

Translated title of the contribution: Immunotherapy in metastasized renal cell carcinoma. Current status and indications for clinical application

R. Heuer, C. Eichelberg, M. Zacharias, H. Heinzer

Klinik für Urologie

Research output: Contribution to journal › Review article › peer-review

Abstract

For a long period of time immunotherapy of metastasized renal cell carcinoma was the only available option. Nowadays, after the introduction of targeted therapy options, such as angiogenesis inhibitors, tyrosinkinase inhibitors or mTOR inhibitors, the question of further indications for immunotherapy arises. This article discusses the impact and options of immunotherapy according to current publications under the aspects of side-effects and indications.

Translated title of the contribution	Immunotherapy in metastasized renal cell carcinoma. Current status and indications for clinical application
Original language	German
Pages (from-to)	1040-1047
Number of pages	8
Journal	Onkologe
Volume	14
Issue number	10
DOIs	https://doi.org/10.1007/s00761-008-1486-y
Publication status	Published - Oct 2008

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00761-008-1486-y

Cite this

@article{64242a571cba49819b0bd4a0790c378b,

title = "Immuntherapie des metastasierten nierenzellkarzinoms. Aktueller stand und indikationen zum klinischen einsatz",

abstract = "For a long period of time immunotherapy of metastasized renal cell carcinoma was the only available option. Nowadays, after the introduction of targeted therapy options, such as angiogenesis inhibitors, tyrosinkinase inhibitors or mTOR inhibitors, the question of further indications for immunotherapy arises. This article discusses the impact and options of immunotherapy according to current publications under the aspects of side-effects and indications.",

keywords = "Cytokines, Immunotherapy, Interferon, Interleukin, Metastasized renal cell carcinoma",

author = "R. Heuer and C. Eichelberg and M. Zacharias and H. Heinzer",

year = "2008",

month = oct,

doi = "10.1007/s00761-008-1486-y",

language = "German",

volume = "14",

pages = "1040--1047",

journal = "Onkologe",

issn = "0947-8965",

publisher = "Springer Medizin",

number = "10",

}

TY - JOUR

T1 - Immuntherapie des metastasierten nierenzellkarzinoms. Aktueller stand und indikationen zum klinischen einsatz

AU - Heuer, R.

AU - Eichelberg, C.

AU - Zacharias, M.

AU - Heinzer, H.

PY - 2008/10

Y1 - 2008/10

N2 - For a long period of time immunotherapy of metastasized renal cell carcinoma was the only available option. Nowadays, after the introduction of targeted therapy options, such as angiogenesis inhibitors, tyrosinkinase inhibitors or mTOR inhibitors, the question of further indications for immunotherapy arises. This article discusses the impact and options of immunotherapy according to current publications under the aspects of side-effects and indications.

AB - For a long period of time immunotherapy of metastasized renal cell carcinoma was the only available option. Nowadays, after the introduction of targeted therapy options, such as angiogenesis inhibitors, tyrosinkinase inhibitors or mTOR inhibitors, the question of further indications for immunotherapy arises. This article discusses the impact and options of immunotherapy according to current publications under the aspects of side-effects and indications.

KW - Cytokines

KW - Immunotherapy

KW - Interferon

KW - Interleukin

KW - Metastasized renal cell carcinoma

UR - https://www.scopus.com/pages/publications/54049092749

UR - https://www.scopus.com/inward/citedby.url?scp=54049092749&partnerID=8YFLogxK

U2 - 10.1007/s00761-008-1486-y

DO - 10.1007/s00761-008-1486-y

M3 - Review article

AN - SCOPUS:54049092749

SN - 0947-8965

VL - 14

SP - 1040

EP - 1047

JO - Onkologe

JF - Onkologe

IS - 10

ER -

Immuntherapie des metastasierten nierenzellkarzinoms. Aktueller stand und indikationen zum klinischen einsatz

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this